arrow
Y

Yongying Jiang

the university of texas-md anderson cancer center
H指数:22
被引数:2,837

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

DCAF11-dependent molecular glue degrader activated by glutathionylation

DCAF11依赖性分子胶降解剂由谷胱甘肽化作用激活

Nature
IF48.5
2026-08-050
OA
Structure-Guided Development of NRAS G12D Inhibitors Based on a 5-Azaindole Core
2026-01-220
PRE
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

纳武利尤单抗联合伊匹木单抗诱导肾髓质癌发生超进展:一项II期试验结果及临床前证据

2025-11-250
OAAI
Allosteric targeting of RIPK1: discovery of novel inhibitors via parallel virtual screening and structure-guided optimization

别构靶向RIPK1:通过平行虚拟筛选和结构导向优化发现新型抑制剂

2025-09-270
PRE
Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors

发现具有协同抗肿瘤活性的新型、高效且口服生物利用的SMARCA2蛋白降解靶向嵌合体,其与Kirsten Rat Sarcoma Viral Oncogene Homologue G12C抑制剂联用。

2025-04-250
PRE
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers
2024-12-040
PRE
Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy
2023-07-129
PRE
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor
2021-10-1323
PREAI
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme

发现IACS-9779和IACS-70465作为靶向吲哚胺2,3-双加氧酶1 (IDO1) 脱辅酶的有效抑制剂

2021-07-2217
PREAI
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers (vol 2, pg 1413, 2020)
2020-12-180
OAAI
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

变构SHP2抑制剂,IACS-13909克服了对奥希替尼的EGFR依赖性和EGFR非依赖性耐药机制

2020-11-0362
OAAI
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

发现具有优异药代动力学和理化特性的临床阶段选择性Glutaminase-1 (GLS-1) 抑制剂IPN60090

2020-10-2962
OAAI
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R
2020-07-2913
PREAI